Lexeo

Stifel starts Lexeo at buy, cites ataxia and Alzheimer’s drug candidates (LXEO)

November 30, 2023

13

ismagilov Stifel has started coverage of newly public Lexeo Therapeutics (NASDAQ:LXEO) with a buy rating, saying it was bullish on…

JP Morgan starts Lexeo at overweight, sees upside with continued de-risking (NASDAQ:LXEO)

November 30, 2023

12

Mikko Lemola/iStock via Getty Images JP Morgan has started coverage of newly public Lexeo Therapeutics (NASDAQ:LXEO) with an overweight rating,…